文献速递慢性肾脏病血液净化与透析肾移植

肾脏生命周期中的RAAS阻断:治疗标准

RAAS blockade in the kidney life-cycle-treatment standard.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本综述总结肾素-血管紧张素-醛固酮系统(RAAS)阻断在整个肾脏生命周期中的证据:在蛋白尿性CKD中获益明确且可延缓进展,非蛋白尿性CKD获益有限;非甾体MRA非奈利酮增强心肾保护;透析人群可能保护残肾功能,肾移植早期启用可能改善长期结局。

要点

  • 蛋白尿性CKD(含晚期)支持RAAS阻断,非蛋白尿性CKD获益有限
  • 非奈利酮在糖尿病合并CKD中增强肾心保护
  • 透析与肾移植人群的RAAS阻断获益与安全性仍有不确定性

核心结论

  • RAAS阻断是贯穿肾脏生命周期的基石治疗,但疗效与安全性随生命周期阶段不同。
  • SGLT2抑制剂与GLP-1受体激动剂与RAAS阻断为互补而非竞争关系。

研究设计与样本

  • 综述,检索并汇总从一级预防到晚期CKD、透析及肾移植的RAAS调控证据。

主要发现

  • ACEI、ARB、直接肾素抑制剂及MRA可延缓CKD进展、减少蛋白尿并降低心血管风险。
  • 非奈利酮在糖尿病合并CKD人群中进一步增强肾脏与心血管保护。
  • 透析人群RAAS阻断可能保护残肾功能并改善心脏结构与功能,甾体MRA获益不确定。
  • 肾移植中RAAS阻断看似安全,早期启用可能改善移植物及患者长期生存。

临床怎么用

  • 蛋白尿性CKD患者应使用RAAS阻断,包括晚期阶段。
  • 糖尿病合并CKD可考虑加用非奈利酮以增强心肾保护。
  • 透析与肾移植患者使用RAAS阻断需个体化评估获益与不确定性。

局限性

  • 非蛋白尿性CKD中RAAS阻断获益有限。
  • 透析人群甾体MRA的获益仍不确定。
  • 肾移植人群RAAS阻断的长期证据仍需积累。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The renin-angiotensin-aldosterone system (RAAS) plays a central role in regulating renal hemodynamics, sodium and water balance, and cardiovascular homeostasis. Chronic RAAS activation contributes to hypertension, proteinuria, inflammation, fluid overload, and fibrosis, making RAAS blockade (RAASb) a cornerstone therapy across the kidney life cycle. Over the past decades, ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor antagonists (MRAs) have demonstrated substantial benefits in slowing chronic kidney disease (CKD) progression, reducing proteinuria, and lowering cardiovascular risk. However, the efficacy and safety of RAASb vary according to the kidney life cycle. Evidence supports its use in proteinuric CKD and even in advanced stages, whereas the benefit in non-proteinuric disease remains limited. Novel non-steroidal MRAs such as finerenone further enhance renal and cardiovascular protection, particularly in persons with diabetes and CKD. In dialysis populations, RAASb may preserve residual kidney function and improve cardiac structure/function, although the benefit of steroidal MRAs remains uncertain. In kidney transplantation, RAASb appears safe and may improve long-term graft and patient survival, particularly when initiated early. The emergence of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists has reshaped therapeutic strategies, with accumulating evidence supporting complementary rather than competing roles with RAASb. This review synthesizes current evidence on RAAS modulation across the kidney life cycle from primary prevention to advanced CKD, dialysis, and transplantation, highlighting both established benefits and areas of current clinical uncertainty.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Moriconi D, Garcia-Carro C, Nuñez J, et al. RAAS blockade in the kidney life-cycle-treatment standard. Nephrol Dial Transplant. 2026. PMID: 42008148. doi:10.1093/ndt/gfag090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。